My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Automotive Stampings hits 52-week high after reporting turnaround in Q3
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the BSE Sensex was up 135.38 points or 0.49%, to Rs 27,510.96.

More than usual volumes were witnessed on the counter. On the BSE, 42,000 shares were traded on the counter so far as against the average daily volumes of 4,976 shares in the past one quarter. The stock had hit a high of Rs 73.25 so far during the day, which is also its 52-week high. The stock had hit a low of Rs 67 so far during the day.

The stock had hit a 52-week low of Rs 32.20 on 29 March 2016. The stock had outperformed the market over the past one month till 24 January 2017, advancing 8.26% compared with the Sensexs 5.13% rise. The scrip had, however, underperformed the market over the past one quarter declining 5.43% as against the Sensexs 2.85% fall.

The small-cap company has equity capital of Rs 15.86 crore. Face value per share is Rs 10.

Automotive Stampings and Assemblies net sales fell 2.4% to Rs 62.80 crore in Q3 December 2016 over Q3 December 2015.

Automotive Stampings and Assemblies is a manufacturer and supplier of sheet metal components, welded assemblies and modules for automobiles.

Powered by Capital Market - Live News

Infibeam spurts after board OKs preferential issue of warrant
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the BSE Sensex was up 130.18 points, or 0.48%, to 27,505.76.

On the BSE, so far 1.22 lakh shares were traded in the counter, compared with average daily volumes of 1.14 lakh shares in the past one quarter. The stock had hit a high of Rs 1,310 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 1,160 so far during the day.

The stock hit a 52-week low of Rs 431.35 on 8 April 2016. The stock had underperformed the market over the past 30 days till 24 January 2017, falling 0.36% compared with the 6.08% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 34.04% as against Sensexs 1.66% decline.

The mid-cap company has equity capital of Rs 53.39 crore. Face value per share is Rs 10.

Infibeam Incorporation said that its board at the meeting duly held yesterday, 24 January 2017, approved issuing one warrant for an aggregate amount not exceeding Rs 60 crore to Bennett Coleman and Company on preferential basis. The warrant is fully convertible into equity shares at Rs 1,375 each (including premium). The proposal is subject to approval of the shareholders of the company in the ensuing extra-ordinary general meeting (EGM) to be held on 22 February 2017.

Further, the company will seek shareholders approval for increasing the limits of inter corporate loans/investments/guarantee, etc. from exiting limit of Rs 1000 crore to Rs 3000 crore. Further, the company will obtain approval for creating charge/mortgage on the companys assets from existing limit of Rs 1000 crore to Rs 3000 crore. The company will also seek shareholders approval for increasing the borrowing limits from Rs 1000 crore to Rs 3000 crore or the aggregate of the paid up capital and free reserves of the company.

On a consolidated basis, net profit of Infibeam Incorporation rose 122.84% to Rs 8 crore on 31.43% rise in net sales to Rs 114.37 crore in Q2 September 2016 over Q2 September 2015.

Infibeam Incorporation is an e-commerce company.

Powered by Capital Market - Live News

Biocon moves higher after strong Q3 earnings
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 107.56 points or 0.39% at 27,483.14.

On the BSE, 89,000 shares were traded on the counter so far as against the average daily volumes of 75,023 shares in the past one quarter. The stock had hit a high of Rs 1,049 and a low of Rs 1,013 so far during the day.

The stock had hit a record high of Rs 1,052.05 on 12 January 2017 and a 52-week low of Rs 430.80 on 12 February 2016. The stock had outperformed the market over the past one month till 24 January 2017, advancing 7.37% compared with the Sensexs 5.13% rise. The scrip had also outperformed the market over the past one quarter, gaining 2.87% as against the Sensexs 2.85% fall.

The large-cap company has equity capital of Rs 100 crore. Face value per share is Rs 5.

Biocons consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) rose 57% to Rs 324 crore in Q3 December 2016 over Q3 December 2015.

Commenting on the companys quarterly performance, Biocons Chairperson and Managing Director, Kiran Mazumdar-Shaw said, the companys strong performance in Q3 December 2016 was led by robust growth of its biologics business with both insulins and biosimilar MAbs gaining traction in Japan and key emerging markets. The companys small molecules and research services businesses also reported strong growth this quarter, she said.

Separately, Biocon before market hours today, 25 January 2017 announced that the Ministry of Health (MoH), Malaysia, has awarded a three year contract, to its subsidiary, Biocon SDN. BHD., Malaysia, for supplying recombinant human insulin (rh-Insulin) formulations manufactured at its large scale biopharmaceutical facility in Johor, Malaysia. Biocons rh-Insulin is Malaysias first locally manufactured biosimilar biologic product approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia, for commercial sales in the country. This marks the commercialization milestone of Biocons first overseas facility in Malaysia.

Biocon SDN. BHD. has been awarded a MYR 300 million (about Rs 460 crore) contract to be serviced over a period of three years for supplying rh-Insulin cartridges and re-usable insulin pens under the Malaysian governments Off-Take Agreement (OTA) initiative, which seeks to encourage local manufacturing of new pharmaceutical products thus lowering the countrys reliance on imports and also enhancing the exports potential. The contract is extendable for additional two years subject to approval by the Government of Malaysia.

Biocon will distribute insulins and insulin delivery devices through CCM Pharmaceuticals, a leading local pharmaceutical player which has an extensive supply chain network to service primary healthcare clinics and hospitals across Malaysia.

Biocon is Indias largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News

Siemens gains after winning order
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the BSE Sensex was up 103.95 points, or 0.38%, to 27,479.53.

On the BSE, so far 8,384 shares were traded in the counter, compared with average daily volumes of 19,295 shares in the past one quarter. The stock had hit a high of Rs 1,185 and a low of Rs 1,168.55 so far during the day.

The stock hit a 52-week high of Rs 1,355.40 on 25 July 2016. The stock hit a 52-week low of Rs 969 on 29 January 2016. The stock had outperformed the market over the past 30 days till 24 January 2017, rising 10.92% compared with the 6.08% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 2.65% as against Sensexs 1.66% decline.

The large-cap company has equity capital of Rs 71.22 crore. Face value per share is Rs 2.

Siemens announced that it has won an order worth approximately Rs 366 crore from Oil and Natural Gas Corporation (ONGC). The order includes supply of material for overhauling of 18 power turbines through zero hour overhaul and time continued overhaul.

Net profit of Siemens rose 1025.8% to Rs 2466.95 crore on 7.5% decline in net sales to Rs 2990.30 crore in Q4 September 2016 over Q4 September 2015.

Siemens focuses on the areas of electrification, automation and digitalization. As on 31 December 2016, Siemens AG held 74.16% stake in Siemens.

Powered by Capital Market - Live News

Wockhardt slips after weak Q3 results
Jan 25,2017

The announcement was made after market hours yesterday, 24 January 2017.

Meanwhile, the BSE Sensex was up 125.24 points, or 0.46%, to 27,500.82.

On the BSE, so far 72,000 shares were traded in the counter, compared with average daily volumes of 1.92 lakh shares in the past one quarter. The stock had hit a high of Rs 671.70 and a low of Rs 656.60 so far during the day.

The stock hit a 52-week high of Rs 1,296 on 29 January 2016. The stock hit a 52-week low of Rs 627 on 27 December 2016. The stock had outperformed the market over the past 30 days till 24 January 2017, rising 7.40% compared with the 6.08% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 20.92% as against Sensexs 1.66% decline.

The mid-cap company has equity capital of Rs 55.27 crore. Face value per share is Rs 5.

Wockhardts total income dropped 10.34% to Rs 1000.81 crore in Q3 December 2016 over Q3 December 2015. Sales fell 7.44% to Rs 995 crore in Q3 December 2016 over Q3 December 2015.

Earnings before interest, tax, depreciation and amortization (EBITDA) fell 75.68% to Rs 18 crore in Q3 December 2016 over Q3 December 2015. EBITDA margin was reported at 1.8% in Q3 December 2016, lower than 6.9% in in Q3 December 2015.

The companys performance during the quarter was affected by subdued business in US market, demonetisation in India and continued remediation costs. UK Business in GBP terms grew by 2% in Q3 December 2016 over Q3 December 2015. India Business of the company grew by 5% in Q3 December 2016 over Q3 December 2015. However, India business during the quarter was de-grown by 18% in Q3 December 2016 over Q2 September 2016 mostly on account of demonetisation.

Wockhardt is a global pharmaceutical and biotech company with presence in USA, UK, Ireland, Mexico, Russia and many other countries.

Powered by Capital Market - Live News

Bharti Airtel declines after poor Q3 results
Jan 25,2017

The result was announced after market hours yesterday, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 91.44 points or 0.33% at 27,467.02.

On the BSE, 72,000 shares were traded on the counter so far as against the average daily volumes of 1.40 lakh shares in the past one quarter. The stock had hit a high of Rs 312.95 and a low of Rs 304.10 so far during the day.

The stock had hit a 52-week high of Rs 384.90 on 28 April 2016 and a 52-week low of Rs 282.30 on 29 January 2016. The stock had outperformed the market over the past one month till 24 January 2017, advancing 7.06% compared with the Sensexs 5.13% rise. The scrip had also outperformed the market over the past one quarter, gaining 3.21% as against the Sensexs 2.85% fall.

The large-cap company has equity capital of Rs 1998.70 crore. Face value per share is Rs 5.

Bharti Airtels consolidated total revenue on an underlying basis adjusted for Africa divested operating units, tower assets sale and merger of Bangladesh operations declined 3% to Rs 23336 crore in Q3 December 2016 over Q3 December 2015.

The companys consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) rose 1.1% to Rs 8570 crore in Q3 December 2016 over Q3 December 2015. EBITDA margin edged up by 1.5% year-on-year at 36.7% in Q3 December 2016, led by Africa margin expansion of 4.9% on an underlying basis.

Bharti Airtels MD and CEO for India & South Asia, Gopal Vittal said, the quarter has seen turbulence due to the continued predatory pricing by a new operator. The present termination costs at 14 paise which are well below cost has resulted in a tsunami of minutes terminating into Airtels network. This has led to an unprecedented year-on-year revenue decline for the industry, pressure on margins and a serious impact on the financial health of the sector.

Vittal added that at the same time revenue market share of Airtel has crossed a lifetime high of 33%.

Bharti Airtels board in its meeting held yesterday, 24 January 2017, approved issuance of non-convertible debentures (NCDs) on a private placement basis. The outstanding under these NCDs shall at all times be within the overall borrowing limits and be subject to a cap of Rs 10000 crore.

Bharti Airtel is a leading global telecommunications company with operations in 18 countries across Asia and Africa.

Powered by Capital Market - Live News

Zee drops after reporting tepid top line growth in Q3
Jan 24,2017

The result was announced during market hours today, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 252.13 points or 0.93% at 27,369.47.

On the BSE, 1.59 lakh shares were traded on the counter so far as against the average daily volumes of 1.22 lakh shares in the past one quarter. The stock had hit a high of Rs 488.60 and a low of Rs 473.50 so far during the day.

The stock had hit a 52-week high of Rs 588.80 on 3 October 2016 and a 52-week low of Rs 350.15 on 17 February 2016. The stock had outperformed the market over the past one month till 23 January 2017, advancing 9.21% compared with the Sensexs 4.13% rise. The scrip had, however, underperformed the market over the past one quarter, declining 7.4% as against the Sensexs 3.42% fall.

The large-cap company has equity capital of Rs 96.04 crore. Face value per share is Rs 1.

On a consolidated basis, Zee Entertainment Enterprises (ZEEL) advertising revenue rose 3.4% to Rs 955.40 crore in Q3 December 2016 over Q3 December 2015. Subscription revenue grew by 13.7% to Rs 593.50 crore in Q3 December 2016 over Q3 December 2015.

Dr. Subhash Chandra, Chairman, ZEEL, commented that the companys growth in advertising revenues and subscription revenues remained strong. Chandra believes that the adverse impact of demonetization is transient and with a strong portfolio of national and regional channels, the company is confident of delivering sustainable growth.

Zee Entertainment Enterprises is one of Indias leading television media and entertainment companies.

Powered by Capital Market - Live News

North Eastern Carrying Corporation jumps after winning order
Jan 24,2017

The announcement was made during trading hours today, 24 January 2017.

Meanwhile, the BSE Sensex was up 242.23 points, or 0.89%, to 27,359.57.

On the BSE, so far 3.34 lakh shares were traded in the counter, compared with average daily volumes of 1.17 lakh shares in the past one quarter. The stock had hit a high of Rs 74.40 so far during the day, which is also 52-week high for the counter. The stock had hit a low of Rs 71.50 so far during the day.

The stock hit a 52-week low of Rs 31.35 on 24 June 2016. The stock had outperformed the market over the past 30 days till 23 January 2017, rising 87.07% compared with the 4.13% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 69.21% as against Sensexs 3.47% decline.

The small-cap company has equity capital of Rs 50.20 crore. Face value per share is Rs 10.

North Eastern Carrying Corporation has been awarded contract worth Rs 400 crore from Tata Steel for transportation of their raw materials and mining products from their Joda and Sukinda mines situated in Odisha.

On a consolidated basis, net profit of North Eastern Carrying Corporation rose 3.03% to Rs 1.70 crore on 3.07% decline in net sales to Rs 124.24 crore in Q2 September 2016 over Q2 September 2015.

North Eastern Carrying Corporation is specialized in offering domestic goods transportation, international goods transportation, commercial goods transportation services, industrial goods transportation along with warehousing services.

Powered by Capital Market - Live News

Heritage Foods moves higher after strong Q3 outcome
Jan 24,2017

The result was announced during market hours today, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 248.74 points or 0.92% at 27,366.08.

On the BSE, 30,000 shares were traded on the counter so far as against the average daily volumes of 7,699 shares in the past one quarter. The stock had hit a high of Rs 972 so far during the day, which is its record high. The stock hit a low of Rs 925 so far during the day.

The stock had hit a 52-week low of Rs 446 on 12 February 2016. The stock had outperformed the market over the past one month till 23 January 2017, advancing 10.88% compared with the Sensexs 4.13% rise. The scrip had also outperformed the market over the past one quarter, gaining 5.35% as against the Sensexs 3.42% fall.

The small-cap company has equity capital of Rs 23.20 crore. Face value per share is Rs 10.

Heritage Foods operates in dairy, retail, agri, bakery and renewable energy segments.

Powered by Capital Market - Live News

Lupin gains after launch of generic drug in US
Jan 24,2017

The announcement was made during market hours today, 24 January 2017.

Meanwhile, the S&P BSE Sensex was up 188.29 points or 0.69% at 27,305.63.

On the BSE, 21,000 shares were traded on the counter so far as against the average daily volumes of 79,217 shares in the past one quarter. The stock had hit a high of Rs 1,501 and a low of Rs 1,480.45 so far during the day.

The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016 and a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 23 January 2017, advancing 2.57% compared with the Sensexs 4.13% rise. The scrip had, however, outperformed the market over the past one quarter, declining 1.09% as against the Sensexs 3.42% fall.

The large-cap company has equity capital of Rs 90.30 crore. Face value per share is Rs 2.

Lupin said it has launched its Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg in the United States having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic version of Janssen Pharmaceuticals, Incs Ortho-Cyclen 28 Tablets (Norgestimate/Ethinyl Estradiol).

Lupins Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg are the AB rated generic equivalent of Janssen Pharmaceuticals, Inc.s Ortho-Cyclen 28 Tablets (Norgestimate/Ethinyl Estradiol). It is indicated for use by females of reproductive potential to prevent pregnancy.

Ortho-Cyclen 28 Tablets had annual US sales of $204 million as per IMS MAT September 2016.

Lupins consolidated net profit rose 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015. The company is scheduled to announce Q3 December 2016 results on 9 February 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership position in the anti-TB segment.

Powered by Capital Market - Live News

Volumes jump at Gujarat Gas counter
Jan 24,2017

Gujarat Gas clocked volume of 5.98 lakh shares by 14:01 IST on BSE, a 208.01-times surge over two-week average daily volume of 3,000 shares. The stock rose 2.70% to Rs 554.10.

Pidilite Industries notched up volume of 62.37 lakh shares, a 207.37-fold surge over two-week average daily volume of 30,000 shares. The stock rose 2.55% to Rs 644.30.

Astral Poly Technik saw volume of 2.54 lakh shares, a 102.95-fold surge over two-week average daily volume of 2,000 shares. The stock fell 0.26% to Rs 380.

Ajanta Pharma clocked volume of 4.39 lakh shares, a 66.93-fold surge over two-week average daily volume of 7,000 shares. The stock fell 5.19% to Rs 1,691.

Kotak Mahindra Bank saw volume of 44.72 lakh shares, a 51.74-fold rise over two-week average daily volume of 86,000 shares. The stock rose 1.18% to Rs 739.50.

Powered by Capital Market - Live News

Trent leads gainers in A group
Jan 24,2017

Trent jumped 7.25% to Rs 225.45 at 13:22 IST after net profit rose 14.02% to Rs 37.23 crore on 11.6% increase in total income to Rs 453.87 crore in Q3 December 2016 over Q3 December 2015. The stock topped the gainers in the BSEs A group. On the BSE, 1.81 lakh shares were traded on the counter so far as against the average daily volumes of 48,000 shares in the past two weeks.

Tata Communications surged 5.06% at Rs 706.30. The stock was second biggest gainer in A group. On the BSE, 2.43 lakh shares were traded on the counter so far as against the average daily volumes of 1.04 lakh shares in the past two weeks.

EID Parrys (India) advanced 4.35% to Rs 295. The stock was third biggest gainer in A group. On the BSE, 79,000 shares were traded on the counter so far as against the average daily volumes of 76,000 shares in the past two weeks.

Shree Cement gained 3.86% at Rs 15,699. The stock was fourth biggest gainer in A group. On the BSE, 325 shares were traded on the counter so far as against the average daily volumes of 768 shares in the past two weeks.

Edelweiss Financial Services rose 3.69% to Rs 113.90. The stock was fifth biggest gainer in A group. On the BSE, 1.08 lakh shares were traded on the counter so far as against the average daily volumes of 1.69 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Bhel gains after bagging order
Jan 24,2017

The announcement was made during trading hours today, 24 January 2017.

Meanwhile, the BSE Sensex was up 120.02 points, or 0.44%, to 27,237.36.

On the BSE, so far 4.63 lakh shares were traded in the counter, compared with average daily volumes of 5.76 lakh shares in the past one quarter. The stock had hit a high of Rs 132.30 and a low of Rs 129 so far during the day.

The stock hit a 52-week high of Rs 162.80 on 8 September 2016. The stock hit a 52-week low of Rs 90.40 on 29 February 2016. The stock had outperformed the market over the past 30 days till 23 January 2017, rising 7.89% compared with the 4.13% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 8.44% as against Sensexs 3.47% decline.

The large-cap company has equity capital of Rs 489.52 crore. Face value per share is Rs 2.

Bharat Heavy Electricals (Bhel), in partnership with ABB, has secured a landmark order from Power Grid Corporation of India. Bhels scope of work, is valued at Rs 1360 crore, for setting up a +800 kilovolt, 6,000 megawatts HVDC Link between the Western Region Grid (Raigarh, Chattisgarh) and the Southern Region Grid (Pugalur, Tamil Nadu).

Bhel reported net profit of Rs 109 crore in Q2 September 2016 compared with net loss of Rs 180.78 crore in Q2 September 2015. Net sales rose 12.1% to Rs 6550.77 crore in Q2 September 2016 over Q2 September 2015.

Bhel is a leader in the power generation and transmission segments in India. In the field of power transmission, Bhel undertakes turnkey projects from concept to commissioning as an EPC contractor for EHV Substations, HVDC Converter Stations and FACTS solutions backed by Power System Studies. The Government of India currently holds 63.06% stake in Bhel (as per the shareholding pattern as on 31 December 2016).

Powered by Capital Market - Live News

HDFC Bank gains after Q3 results
Jan 24,2017

The result was announced during trading hours today, 24 January 2017.

Meanwhile, the BSE Sensex was up 115.19 points, or 0.42%, to 27,232.53.

On the BSE, so far 63,000 shares were traded in the counter, compared with average daily volumes of 2.02 lakh shares in the past one quarter. The stock had hit a high of Rs 1,261 and a low of Rs 1,250 so far during the day.

The stock hit a record high of Rs 1,318.20 on 23 September 2016. The stock hit a 52-week low of Rs 928.80 on 29 February 2016. The stock had outperformed the market over the past 30 days till 23 January 2017, rising 4.92% compared with the 4.13% rise in the Sensex. The scrip had also outperformed the market in past one quarter, falling 0.45% as against Sensexs 3.47% decline.

The large-cap private sector bank has equity capital of Rs 511.07 crore. Face value per share is Rs 2.

HDFC Banks gross non-performing assets (NPAs) stood at Rs 5232.27 crore as on 31 December 2016 as against Rs 5069.04 crore as on 30 September 2016 and Rs 4255.20 crore as on 31 December 2015.

The ratio of gross NPAs to gross advances stood at 1.05% as on 31 December 2016 as against 1.02% as on 30 September 2016 and 0.97% as on 31 December 2015.

The ratio of net NPAs to net advances stood at 0.32% as on 31 December 2016 as against 0.30% as on 30 September 2016 and 0.29% as on 31 December 2015.

The banks provisions and contingencies (excluding tax provisions) rose 9.47% to Rs 715.78 crore in Q3 December 2016 over Q3 December 2015.

CASA deposit growth saw a spurt largely attributable to the demorietisation exercise, with current account deposits growing by 36.7% over the previous year to reach Rs 101239 crore and savings account deposits growing by 37.8% over the previous year to reach Rs 186634 crore. Time deposits were at Rs 346,832 crore, an increase of 10.3% over the previous year resulting in CASA proportion of 45% as on 31 December 2016.

Powered by Capital Market - Live News

Nocil gains after good Q3 results
Jan 24,2017

The result was announced after market hours yesterday, 23 January 2017.

Meanwhile, the S&P BSE Sensex was up 121.28 points or 0.45% at 27,238.62.

On the BSE, 3.10 lakh shares were traded on the counter so far as against the average daily volumes of 3.22 lakh shares in the past one quarter. The stock had hit a high of Rs 77.20 and a low of Rs 74.50 so far during the day.

The stock had hit a 52-week high of Rs 82.35 on 20 October 2016 and a 52-week low of Rs 37.65 on 12 February 2016. The stock had outperformed the market over the past one month till 23 January 2017, advancing 13.42% compared with the Sensexs 4.13% rise. The scrip had also outperformed the market over the past one quarter, declining 3.3% as against the Sensexs 3.42% fall.

The small-cap company has equity capital of Rs 163.58 crore. Face value per share is Rs 10.

Nocil manufactures basic organic chemicals.

Powered by Capital Market - Live News